Q3 2025 13F Holders as of 30 Sep 2025
-
Type / Class
-
Equity / Voting Common Stock, par value $0.0001 per share
-
Shares outstanding
-
5,381,598
-
Number of holders
-
33
-
Total 13F shares, excl. options
-
2,651,648
-
Shares change
-
-52,752
-
Total reported value, excl. options
-
$25,986,937
-
Value change
-
+$21,301
-
Number of buys
-
16
-
Number of sells
-
-14
-
Price
-
$9.80
Significant Holders of Aligos Therapeutics, Inc. - Voting Common Stock, par value $0.0001 per share (ALGS) as of Q3 2025
42 filings reported holding ALGS - Aligos Therapeutics, Inc. - Voting Common Stock, par value $0.0001 per share as of Q3 2025.
Aligos Therapeutics, Inc. - Voting Common Stock, par value $0.0001 per share (ALGS) has 33 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 2,651,648 shares
of 5,381,598 outstanding shares and own 49% of the company stock.
Largest 10 shareholders include Woodline Partners LP (468,199 shares), Deep Track Capital, LP (444,110 shares), Alyeska Investment Group, L.P. (412,000 shares), Sio Capital Management, LLC (335,937 shares), READYSTATE ASSET MANAGEMENT LP (203,113 shares), VANGUARD GROUP INC (171,689 shares), ADAGE CAPITAL PARTNERS GP, L.L.C. (140,000 shares), BAKER BROS. ADVISORS LP (83,055 shares), HHLR ADVISORS, LTD. (76,247 shares), and LPL Financial LLC (55,120 shares).
This table shows the top 33 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.